ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Expert Interviews
The Health Optimization Doctors RoundTable: High Hematocrit Not Important?
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="tareload" data-source="post: 256796"><p>Also TRT arm showed higher incidence of DVT/PE (tertiary end point). Marginal <a href="https://bestpractice.bmj.com/info/toolkit/learn-ebm/how-to-calculate-risk/" target="_blank">hazard ratio </a>and read fine print in Table 2. No multiplicity correction for secondary and higher endpoints.</p><p></p><p></p><p>[ATTACH=full]33686[/ATTACH]</p><p></p><p>Sure looks like reasonable evidence for more clots in the T group. Huge effect size? No. Significant? Likely. Nothing special about using p value of 0.05 to calculate HR. Could use p value of 0.1 or 0.001 or whatever. I will spare everyone a deep dive on statistical significance, means comparisons, p values unless someone really wants it.</p><p></p><p>This study was about as mild as you can get from invention standpoint. To Nelson's point, an injection study or TOT treatment arm would be illuminating. Evidently I am only person who knows Docs who have had patients throw a clot with TRT, blood pressure, symphathetic NS overdrive, etc. Forget the long term wear and tear as well.. The TOT Knights of the Roundtable and their patients are immune from any T adverse events. Must be nice.</p></blockquote><p></p>
[QUOTE="tareload, post: 256796"] Also TRT arm showed higher incidence of DVT/PE (tertiary end point). Marginal [URL='https://bestpractice.bmj.com/info/toolkit/learn-ebm/how-to-calculate-risk/']hazard ratio [/URL]and read fine print in Table 2. No multiplicity correction for secondary and higher endpoints. [ATTACH type="full" alt="1687281261281.png"]33686[/ATTACH] Sure looks like reasonable evidence for more clots in the T group. Huge effect size? No. Significant? Likely. Nothing special about using p value of 0.05 to calculate HR. Could use p value of 0.1 or 0.001 or whatever. I will spare everyone a deep dive on statistical significance, means comparisons, p values unless someone really wants it. This study was about as mild as you can get from invention standpoint. To Nelson's point, an injection study or TOT treatment arm would be illuminating. Evidently I am only person who knows Docs who have had patients throw a clot with TRT, blood pressure, symphathetic NS overdrive, etc. Forget the long term wear and tear as well.. The TOT Knights of the Roundtable and their patients are immune from any T adverse events. Must be nice. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Expert Interviews
The Health Optimization Doctors RoundTable: High Hematocrit Not Important?
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top